Emblation will be attending Europe’s largest podiatry conference from the 17th – 19th November at Glasgow’s SECC.
Emblation’s CEO, Gary Beale, will be joining our team for the duration of the 3 day conference to answer any questions about Swift’s pioneering technology. We will also be joined by experienced Swift users, who will be sharing their experiences about the treatment and our Marketing Director, Jonathan Williamson, will be on hand to discuss how Emblation can support Swift clinics to market this revolutionary treatment. Continue reading
Emblation will be exhibiting at the 2016 FIP World Congress of Podiatry, 26th -28th May, in Montreal, Canada.
This event, which is held every three years, is the largest gathering of international foot and ankle practitioners/specialists and provides professionals, industry and academia practicing within this field with the opportunity to connect. Continue reading
Emblation will be officially launching Swift at the College of Podiatry Annual Conference, 19th – 21st November in Harrogate.
The College of Podiatry Annual Conference is the largest professional podiatry event in Europe, with over 1,500 senior podiatrists attending the event. Continue reading
Emblation will be exhibiting at Medica from the 16th – 19th November in Düsseldorf, Germany.
With over 128,000 professional visitors from over the world, Medica is the world’s largest medical trade fair. Continue reading
Emblation is pleased to be attending the British Association of Dermatologists’ Annual Meeting, held from the 7th – 9th of July 2015 at Manchester Central, Manchester, UK.
The event will host a wide range of presentations from experts in various areas of dermatology, including a public lecture from Dr Christian Jessen on ‘Manifestations of Skin Problems’.
Dr Ivan Bristow – the UK’s leading authority on podiatric dermatology – will be conducting a two-day seminar on the 19th and 20th of June, 2015 at the Rosseau Muskoka Resort and Spa in Ontario, Canada – concerning recent developments in podiatric dermatology, as well as introducing dermoscopy as a new aid in the diagnosis of skin lesions.
Emblation will be exhibiting at the Australasian Podiatry Conference held between the 6-8 May 2015 at the Gold Coast Convention and Exhibition Center in Broadbeach, Queensland, Australia.
The U.S. Patent and Trademark Office has granted Emblation a Notice of Allowance for U.S. Patent Application No. 13/810320, with claims that cover methods for compact thermal interfacing in medical and industrial microwave applications.
CEO Gary Beale stated, “this Notice of Allowance represents a significant improvement in microwave heat-sink technology applicable to industrial and medical microwave generators.
Emblation is proud to be at the forefront of what is a rapidly growing field of medicine, and the further implementation of this technology will allow for a new type of very compact and efficient microwave generator.”
One of the challenges facing product designers in the field of microwave ablation is how to accommodate the necessary cooling requirements for high power microwave devices. This has traditionally constrained designers and resulted in bulky enclosures, which is in stark contrast to modern compact product design approach. This also presents logistical and marketing constraints in dealing with large heavy equipment boxes which do not aesthetically complement the compact medical devices they support.
This new patent covers a novel method of creating an efficient compact cooling solution that improves the cooling efficiency and significantly compresses the overall size of enclosure required for microwave generators compared to using traditional heat-sinking techniques.
Emblation recently announced that the U.S. Patent and Trademark Office has granted a Notice of Allowance for U.S. Patent Application No. 13/509,835, with claims that cover methods for measuring forward and reflected power in medical and industrial microwave applications.
CEO Gary Beale stated, “once issued, this patent represents a significant step forward for safety in microwave ablation devices.
Emblation is proud to be at the forefront of what is a rapidly growing field of medicine, and the further implementation of this technology will allow for fundamentally safer procedures and the potential for more effective treatments.”
One of the challenges facing product designers in the field of microwave ablation is how to accommodate the measurement of varying impedance and phase where using standard components that are generally calibrated for typical industrial applications, where the impedance match is fixed.
In medical microwave systems the measurement of forward and reflected power is often used as a safety mechanism to monitor treatments, detect and react to device failures, connection issues and potential misuse. Any inaccuracy in these measurements has the potential to result in either insufficient power being delivered – resulting in poor treatments and a perception of unreliability, or excessive power being administered – potentially causing serious patient injury.
This new patent covers a method of measurement that operates independent of load conditions – thereby ensuring a stable and regulated output power and a true measurement of forward and reflected power.